Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Castle Biosciences (CSTL) Stock Price & Analysis
344 Followers
CSTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.26 - $26.70
Previous Close$24.33
Volume839.81K
Average Volume (3M)243.64K
Market Cap
$671.68M
Enterprise Value$443.89M
Total Cash (Recent Filing)$243.10M
Total Debt (Recent Filing)$15.31M
Price to Earnings (P/E)-21.2
Beta1.92
Next Earnings
Aug 05, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding27,607,183
10 Day Avg. Volume265,828
30 Day Avg. Volume243,644
Standard Deviation0.18
R-Squared0.07
Alpha0.00951
Financial Highlights & Ratios
Price to Book (P/B)2.29
Price to Sales (P/S)10.16
Price to Cash Flow (P/CF)8.40
P/FCF Ratio6.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit2.54
Enterprise Value/Ebitda-6.15
Forecast
1Y Price Target
$33.83Price Target Upside39.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences Unveils Informative Management Presentation Slides
PremiumCompany Announcements
Castle Biosciences Secures Loan and Reshuffles BoardBulls Say, Bears Say
Bulls Say
Financial PerformanceCastle reported adjusted revenues well ahead of analyst estimates, reflecting strong financial performance.
Market Share GrowthDecisionDx-Melanoma currently commands a significant market share with a clear strategy to more than double its presence.
Strategic DevelopmentsThe company's strategy of advancing its dermatology franchise and investing in new verticals is poised to create shareholder value.
Bears Say
Insurance Coverage ConcernsThe wait for finalization of the LCD which could eliminate CMS coverage of Dx-SCC.
Legal ChallengesCSTL disclosed an OIG subpoena in its 10-K, which could pressure shares.
Regulatory UncertaintyOngoing uncertainty related to the pending Novitas decision regarding Dx-SCC contributes to the uncertainty in the company's financial projections.
---
Ownership Overview
19.11% Insiders
26.64% Mutual Funds
26.64% Other Institutional Investors
27.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $9.26 and its highest was $26.70 in the past 12 months.
What is Castle Biosciences’s market cap?
Currently, no data Available
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Aug 05, 2024 which is in 93 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on May 02, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.242.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 27,607,183 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went up 6.524%.
Which hedge fund is a major shareholder of Castle Biosciences?
Among the largest hedge funds holding Castle Biosciences’s share is Deerfield Management Company, LP. It holds Castle Biosciences’s shares valued at 21M.
---
Castle Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (39.05% Upside)
$33.83 (39.05% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 42.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.19%
12-Months-Change
Fundamentals
Return on Equity
-7.82%
Trailing 12-Months
Asset Growth
7.41%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
CSTL Company Deck
---
CSTL Earnings Call
Q1 2024
0:00 / 0:00
---
CSTL Stock 12 Months Forecast
Average Price Target
$33.83
▲(39.05% Upside)
Technical Analysis
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+23.26%
reiterated a buy rating 6 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +23.26% per trade.
---